News Quantified

BLRX – biolinerx ltd. - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]

BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]

BioLineRx GAAP EPS of $0.00 beats by $0.68, revenue of $1.18M misses by $0.3M [Seeking Alpha]

BioLineRx Reports 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Form 20-F/A BioLineRx Ltd. For: Dec 31

Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Serlin Philip A

Form 6-K BioLineRx Ltd. For: Mar 26

Form 6-K BioLineRx Ltd. For: Mar 23

Form 20-F BioLineRx Ltd. For: Dec 31

Top News Gainers

12/6 BIOLINERX LTD/S (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. 20.3%

2/19 Form CT ORDER BioLineRx Ltd. 7.5%

5/28 Form 6-K BioLineRx Ltd. For: May 28 7.0%

1/13 BIOLINERX LTD/S (NASDAQ: BLRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.75 price target on the stock. 6.0%

4/7 BioLineRx up big ahead of key data readout [Seeking Alpha] 4.0%

3/30 BIOLINERX LTD/S (NASDAQ: BLRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock. 3.9%

7/2 Form 6-K BioLineRx Ltd. For: Jul 02 2.7%

7/30 Form 20-F/A BioLineRx Ltd. For: Dec 31 2.7%

5/14 Q1/2019 3/31/2019 EPS -0.050 ZacksConsensus -0.050 ActVsEst 0.000 - In-Line 2.7%

3/12 BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 2.2%

Top News Decliners

12/5 BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer -27.1%

5/7 Form 6-K BioLineRx Ltd. For: May 07 -19.8%

12/13 Form 6-K BioLineRx Ltd. For: Dec 13 -13.1%

11/5 BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients -12.9%

9/3 BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors -10.0%

8/6 BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update -8.9%

11/6 BIOLINERX LTD/S (NASDAQ: BLRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.6%

3/12 BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update -8.4%

12/14 BIOLINERX LTD/S (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. -7.5%

6/28 BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares -6.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day